Imho the article is missing a section with regards to telomere biology disorders and related diseases:
https://www.nature.com/articles/s41576-022-00527-z Genetics of human telomere biology disorders
https://www.annualreviews.org/content/journals/10.1146/annurev-genom-010422-091101 The Role of Telomeres in Human Disease
https://en.wikipedia.org/wiki/Danazol#Research
A 2016 phase I/II prospective study orally administered 800 mg per day to 27 patients with telomere diseases. The primary efficacy endpoint was a 20% reduction in the annual rate of telomere attrition measured. Toxic effects formed the primary safety endpoint. The study was halted early, after telomere attrition was reduced in all 12 patients who could be evaluated. 12 of 27 patients achieved the primary efficacy end point, 11 of whom increased telomere length at 24 months. Hematologic responses (secondary efficacy endpoint) occurred in 10 of 12 patients who could be evaluated at 24 months. Elevated liver-enzyme levels and muscle cramps (known adverse effects) of grade 2 or less occurred in 41% and 33% of the patients, respectively.[1] Agentjoerg (talk) 13:47, 8 November 2024 (UTC)